Editors’ Webcast: Major Opportunity in Minor Cannabinoids



Thu, Aug 18, 2022 2:00 PM EDT Industry experts break down the science behind minor cannabinoids and the regulatory best practices of manufacturing finished products so that you can find major success in minor cannabinoids.

Register Free: https://www.nutritionaloutlook.com/no_w/hemp_CBD

Event Overview:

Cannabidiol (CBD) is just the tip of the iceberg when it comes to the cannabinoids found in hemp. And with the popularity of CBD reaching enormous heights, minor cannabinoids are poised to experience similar success by offering a point of differentiation. Certain minor cannabinoids, like delta-8 THC, are even garnering controversy, causing some states to outright ban them. However, many more minor cannabinoids exist that offer an opportunity for more manufacturers to break into the hemp cannabinoid product category.

Key Learning Objectives:

  • Discuss minor cannabinoids, their potential therapeutic benefits, and potential dosage formats
  • Discuss Delta-8 THC, how it’s made, how it differs from other cannabinoids, and whether it has a future in the dietary supplement space
  • Understand the regulatory pitfalls and best practices of manufacturing products with minor cannabinoids derived from hemp

Who Should Attend:

  • Manufacturers of dietary supplements and functional foods and beverages who are currently manufacturing cannabinoid products or looking to enter the space


Nicole Brown
Chief Innovation Officer
Open Book Extracts

Nicole Brown serves as Chief Innovation Officer for North Carolina-based Open Book Extracts (OBX), a foremost ingredient manufacturer and product development manufacturer and supplier focused on cannabinoid-enabled (CBD) health and wellness. Nicole channels data-driven consumer insights into a long-term course of action, delivering immediately usable product innovation, and also drives awareness and thought leadership by overseeing strategic marketing efforts, including PR, event marketing, advertising, and partnerships.

Ashish Talati
Amin Talati Wasserman

Ashish Talati leads Amin Talati Wasserman’s FDA practice and is one of the industry’s foremost experts on FDA regulatory matters. Talati primarily counsels clients on matters of regulatory compliance, helping them anticipate and address regulatory issues in their day-to-day business operations and strategic planning. He also advocates on their behalf before the FDA, FTC, Customs, USDA, and other federal agencies. He is considered a leading authority in the areas of Generally Recognized as Safe (GRAS) requirements and New Dietary Ingredients (NDI). Considered a creative and strategic partner by his clients, Talati works with companies all over the globe and is a trusted advisor at every step of the product life cycle, including product formulation, safety and efficacy studies, product launch, and ongoing marketing and sales.

Register Free: https://www.nutritionaloutlook.com/no_w/hemp_CBD

Related Content
© 2024 MJH Life Sciences

All rights reserved.